Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
InVisionFirst®-Lung Liquid Biopsy
- Liquid Biopsy
The InVisionFirst®-Lung liquid biopsy test is a 37-gene next-generation sequencing assay performed on cell-free circulating tumor DNA in peripheral blood to detect oncogenic driver mutations and therapy targets in non-small cell lung cancer (NSCLC). This assay demonstrated 98% concordance with tissue in clinical validation.
SNVs + indel hotspots: ALK, AKT1, BRAF, CCND1, CTNNB1, EGFR, ERBB2, ESR1, FGFR2, FGFR3, GATA3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KRAS, KIT, MAP2K1, MET, MYC, NFE2L2, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PPP2R1A, ROS1, U2AF1 SNVs + indel exon coverage: PTEN (70%), CDKN2A, STK11, TP53 (88-100%) Fusions: ALK, NTRK1, RET, ROS1 CNV: EGFR, ERBB2, FGFR1, MET including exon 14 deletion
Turnaround time
7 Days
Level of Service
- Global
New York Approved: No
Specimen Requirements
Peripheral blood: two x 10 mL Streck Cell-Free DNA BCT® tubes
Storage and Transportation
Storage & Transportation: Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
CPT Code(s)*
0388U
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: February 12, 2025